Mineralys Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
19.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$4.43next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA PDUFA Target Action Date for Lorundrostat | 22 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investments Quarterly646.1MTarget: Sufficient to fund operations into 2028
Quarterly Net Loss Quarterly-39.3MTarget: Narrowing losses through operational discipline
Watch Items
- FDA PDUFA Target Action Date for LorundrostatTrigger: December 22, 2026Action: Monitor FDA communications, complete pre-launch commercial readiness, and prepare medical affairs and sales teams.
- ADVANCE-HTN Phase 3 Trial Enrollment and Data ReadoutAction: Track patient recruitment dynamics and clinical site expansion to ensure timeline adherence.
Research as of 19 Jun 2026